- GSK will invest $30 billion across the United States in research and development and supply chain infrastructure over the next five years
- The investment includes $1.2 billion for new manufacturing facilities, AI technologies, and a biologics factory in Pennsylvania, creating hundreds of highly skilled US jobs
GSK announced plans to invest $30 billion across the United States in research and development and supply chain infrastructure over the next five years. The investment includes a new $1.2 billion commitment to advanced manufacturing facilities and AI and advanced digital technologies. The announcement follows other pharmaceutical companies prioritising US investment, including AstraZeneca’s pledge of a $50 billion investment in the US by 2030 and Merck’s relocation of UK research operations to existing sites, primarily in the US.
The $1.2 billion investment encompasses construction of an additional biologics flex factory at Upper Merion, Pennsylvania, scheduled to begin construction in 2026. The facility will produce medicines for respiratory diseases including COPD and asthma, as well as cancer treatments for hematological, gynecological, lung and other solid tumours. The investment also includes new AI and digital technology capabilities across GSK’s existing five manufacturing sites in Pennsylvania, North Carolina, Maryland, and Montana.
“This week’s state visit brings together two countries that have led the world in science and healthcare innovation. We are proud to be part of both,” says GSK CEO Emma Walmsley.
She added that GSK was “committing to invest at least $30 billion in the United States over the next 5 years, further bolstering the already strong R&D and supply chain we have in the country.” US Commerce Secretary Howard Lutnick described the commitment as a “landmark investment” that “will create tens of thousands of American jobs and ensure that critical medicines and technologies are developed and manufactured right here on US soil.”
The broader $30 billion commitment includes capital investments across GSK’s US supply chain and increased R&D investment in drug discovery, development and clinical trial activity. The United States is expected to rank first globally for the number of studies, sites, and clinical trial participants conducted by GSK over the next five years. UK Prime Minister Keir Starmer said the investment was a “powerful example of how UK-US collaboration is driving real-world impact.”
“The investment is a powerful example of how UK-US collaboration is driving real-world impact – improving people’s health, creating opportunity, and turbocharging growth,” says UK Prime Minister Keir Starmer.
GSK has now committed approximately $2 billion in US manufacturing investments over the last 12 months. In October 2024, the company began construction of an $800 million facility at its Marietta, Pennsylvania site. The new manufacturing investments will create hundreds of highly skilled jobs, adding to GSK’s approximately 15,000-strong US workforce.
